Analyst Adds Hinge Health to Watchlist After 53% Revenue Growth as Nasdaq 100 Slips
Updated
Updated · TheStreet · Aug 24
Analyst Adds Hinge Health to Watchlist After 53% Revenue Growth as Nasdaq 100 Slips
1 articles · Updated · TheStreet · Aug 24
Summary
Hinge Health was added to the analyst’s shopping list, though no position was taken, as weak Monday trading and bond worries kept the focus on preserving cash.
The appeal is company-specific strength: second-quarter revenue rose 53% to $213 million, beat a $201.5 million consensus, and management lifted guidance for the third time this year.
That momentum follows earlier catalysts including a February earnings beat, a June investor day, and a $105 million deal for Cylinder Health that expands Hinge into digestive care.
Shares have climbed from the mid-$60s to nearly $90 since June and are now basing near highs, holding the 20-day moving average just below $92 resistance.
September-quarter consensus calls for $223.7 million in revenue and $0.61 a share—both up about 45% year over year—making Hinge a candidate to buy when broader market conditions improve.